Cargando…

Weaker SARS-CoV-2 vaccine responses in nonalcoholic fatty liver disease with advanced liver fibrosis

BACKGROUND: SARS-CoV-2 vaccine responses that could harbor potential risks to chronic liver diseased patients. AIMS: To assess immune response following Pfizer's SARS-CoV-2 vaccine in patients with different liver fibrosis severities of nonalcoholic fatty liver disease (NAFLD). METHODS: Clinica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hakimian, David, Amer, Johnny, Jammal, Alaa, Shafrir, Asher, Milgrom, Yael, Masarowah, Mohammad, Hazou, Wadi, Ishay, Yuval, Imam, Ashraf, Francis, Adi, Khalaileh, Abed, Safadi, Rifaat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Regular paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598407/ https://www.ncbi.nlm.nih.gov/pubmed/37885772 http://dx.doi.org/10.1016/j.jvacx.2023.100359

Ejemplares similares

Advanced Liver Fibrosis Correlates With Impaired Efficacy of Pfizer‐BioNTech COVID‐19 Vaccine in Medical Employees
por: Shafrir, Asher, et al.
Publicado: (2022)

SARS-CoV-2 vaccine alleviates disease burden and severity in liver transplant recipients even with low antibody titers
por: Khalaileh, Abed, et al.
Publicado: (2023)

Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis
por: Safadi, Rifaat, et al.
Publicado: (2021)

Patients with low ALT levels are at increased risk for severe COVID-19
por: Genzel, Dor, et al.
Publicado: (2023)

Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease
por: Daher, Saleh, et al.
Publicado: (2018)

Prognosis and Treatment of Liver Transplant Recipients in the COVID-19 Era: A Literature Review
por: Imam, Ashraf, et al.
Publicado: (2020)

Sodium(+)/taurocholate cotransporting polypeptide as target therapy for liver fibrosis
por: Salhab, Ahmad, et al.
Publicado: (2022)

25(OH) D3 alleviate liver NK cytotoxicity in acute but not in chronic fibrosis model of BALB/c mice due to modulations in vitamin D receptor
por: Salhab, Ahmad, et al.
Publicado: (2020)

Endoscopic Ultrasound‐Guided Angiotherapy for Gastric Varices: A Single Center Experience
por: Khoury, Tawfik, et al.
Publicado: (2018)

Insulin signaling as a potential natural killer cell checkpoint in fatty liver disease
por: Amer, Johnny, et al.
Publicado: (2018)

Natural Killer Cell-Dependent Anti-Fibrotic Pathway in Liver Injury via Toll-Like Receptor-9
por: Abu-Tair, Lina, et al.
Publicado: (2013)

Both high and low pre-infection glucose levels associated with increased risk for severe COVID-19: New insights from a population-based study
por: Shauly-Aharonov, Michal, et al.
Publicado: (2021)

Parameters Suggesting Spontaneous Passage of Stones from Common Bile Duct: A Retrospective Study
por: Khoury, Tawfik, et al.
Publicado: (2019)

The Immune Interplay between Thyroid Papillary Carcinoma and Hepatic Fibrosis
por: Muhanna, Nidal, et al.
Publicado: (2015)

Weaker is better
por: Nyberg, Kara A.
Publicado: (2005)

The Weaker Sex
por: Hess, Sharon Folkenroth
Publicado: (2022)

The Association Between Proton Pump Inhibitors and COVID-19 is Confounded by Hyperglycemia in a Population-Based Study
por: Shafrir, Asher, et al.
Publicado: (2022)

Low Serum Lysosomal Acid Lipase Activity Correlates with Advanced Liver Disease
por: Shteyer, Eyal, et al.
Publicado: (2016)

Weaker together or weaker apart? Great power relations after the coronavirus
por: Biscop, Sven
Publicado: (2020)

Alleviation of Hepatic Steatosis by Alpha-Defensin Is Associated with Enhanced Lipolysis
por: Maraga, Emad, et al.
Publicado: (2023)

Our Weaker Brethren
Publicado: (1893)

The A3 adenosine receptor agonist, namodenoson, ameliorates non-alcoholic steatohepatitis in mice
por: Fishman, Pnina, et al.
Publicado: (2019)

Pulmonary embolism risk in hospitalized patients with nonalcoholic fatty liver disease: A case-control study
por: Zeina, Abdel-Rauf, et al.
Publicado: (2022)

On weaker forces than gravity
por: De Rújula, Alvaro
Publicado: (1986)

Weaker neural suppression in autism
por: Schallmo, Michael-Paul, et al.
Publicado: (2020)

Case Marking in Hindi as the Weaker Language
por: Montrul, Silvina, et al.
Publicado: (2019)

COVID-19: Is there a weaker sex?
por: Gómez-Ochoa, Sergio Alejandro, et al.
Publicado: (2020)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Amjad, Waseem, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease
por: Bebawi, Emmanuel, et al.
Publicado: (2023)

Nonalcoholic fatty liver disease stratification by liver lipidomics
por: Vvedenskaya, Olga, et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease after Liver Transplant
por: Shetty, Akshay, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease and non-liver comorbidities
por: Manikat, Richie, et al.
Publicado: (2023)

Kidney Transplantation in the Times of COVID-19 – A Literature Review
por: Imam, Ashraf, et al.
Publicado: (2020)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Weaker Dental Enamel Explains Dental Decay
por: Vieira, Alexandre R., et al.
Publicado: (2015)

Weaker Self-Esteem in Adolescence Predicts Smoking
por: Saari, Antti J., et al.
Publicado: (2015)

Why make a strong muscle weaker?
por: Iorga, Bogdan, et al.
Publicado: (2021)

Comparison of hospital worker anxiety in COVID-19 treating and non-treating hospitals in the same city during the COVID-19 pandemic
por: Milgrom, Yael, et al.
Publicado: (2020)

Laparoscopic cystectomy for pancreatic echinococcosis: A case report and literature review
por: Imam, Ashraf, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hl53pinmsait3v9uru1og3eon0